Company profile
Ticker
PPD
Exchange
Website
CEO
David S. Simmons
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
0972792 B.C. LTD • AbC.R.O., Inc. • Access to Patients, LLC • Acurian, Inc. • APBI Finance Corporation • Applied Bioscience International, LLC • ATP, LLC • CCBR (Beijing) Company Limited • CCBR Asia Ltd. • CENTER FOR CLINICAL AND BASIC RESEARCH (BEIJING) LIMITED ...
IRS number
453806427
PPD stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
20 Dec 21
S-8 POS
Registration of securities for employees (post-effective amendment)
8 Dec 21
8-K
Termination of a Material Definitive Agreement
8 Dec 21
25-NSE
Exchange delisting
8 Dec 21
10-Q
2021 Q3
Quarterly report
28 Oct 21
8-K
PPD Reports Third Quarter and Year-To-Date 2021 Results
27 Oct 21
10-Q
2021 Q2
Quarterly report
29 Jul 21
8-K
PPD Reports Second Quarter and Year-To-Date 2021 Results
28 Jul 21
DEFR14C
Revised information
26 May 21
DEFM14C
Information related to merger
25 May 21
Transcripts
PPD
Earnings call transcript
2021 Q3
28 Oct 21
PPD
Earnings call transcript
2021 Q2
31 Jul 21
PPD
Earnings call transcript
2021 Q1
28 Apr 21
PPD
Earnings call transcript
2020 Q4
25 Feb 21
PPD
Earnings call transcript
2020 Q3
28 Oct 20
PPD
Earnings call transcript
2020 Q2
10 Aug 20
PPD
Earnings call transcript
2020 Q1
11 May 20
Latest ownership filings
4
Science 37 Holdings, Inc.
14 Mar 24
SC 13G/A
H&F Corporate Investors VII, Ltd.
8 Feb 22
SC 13G/A
Abu Dhabi Investment Authority
2 Feb 22
4
Group Management L.L.C. Carlyle
9 Dec 21
SC 13G
Carlyle Group Inc.
9 Dec 21
4
Change in insider ownership
8 Dec 21
4
Allen R Thorpe
8 Dec 21
4
David Michael Johnston
8 Dec 21
4
Colin Hill
8 Dec 21
4
Karen Kaucic
8 Dec 21
Financial summary
Quarter (USD) | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Mar 24 | Thermo Fisher Scientific | Common Stock | Dispose U | Yes | No | 5.75 | 868,990 | 5.00 mm | 0 |